The FDA's Upcoming Computer Software Assurance Guidance
The FDA is expected to release a new guidance document, Computer Software Assurance for Manufacturing, Operations and Quality System Software. This new guidance is highly anticipated because it will actually streamline some of your computer software systems.
The FDA is leaning towards a Case for Quality (CfQ) approach with less emphasis on a compliance approach, allowing device manufacturers to focus on enhancing device quality and patient safety.
What's Inside
- What the FDA's anticipated Computer Software Assurance for Manufacturing, Operations and Quality System Software guidance is — and why it is expected to streamline software systems.
- The shift from a compliance-first mindset to a Case for Quality (CfQ) approach focused on device quality and patient safety.
- The two issues the FDA identified that drove this new approach: lagging adoption of automation and difficulty finding the root cause of quality issues.
- Why outdated compliance approaches and perceived regulatory burden have slowed implementation of new technologies in the industry.
- How Computer Software Assurance (CSA) reframes validation effort around risk and patient safety.
Why the FDA Is Changing Its Approach
Two issues identified by the FDA have driven their new approach:
1. The industry lags in implementation of automated systems and new technologies due to the lack of clarity, outdated compliance approaches, and perceived regulatory burden.
2. Companies often struggle to understand the root cause of issues in order to improve product quality.
Together, these issues point to the same conclusion: a documentation-heavy, compliance-first model can actually stand in the way of quality. CSA is designed to redirect effort toward the testing and assurance activities that protect patients. For a deeper look at how this connects to existing software regulation, see our overview of 21 CFR Part 11 compliance.
USDM's point of view: For life sciences manufacturers, the move to Computer Software Assurance is not about doing less — it is about doing the right work. By anchoring effort to risk and patient safety instead of paperwork, teams can adopt automation and new technologies faster while keeping quality at the center. USDM helps device, pharma, and biologics organizations apply a risk-based CSA mindset across their quality systems and connect it to broader data integrity in life sciences goals.
To continue reading, download the white paper.
Frequently Asked Questions About Computer Software Assurance
What is Computer Software Assurance (CSA)?
Computer Software Assurance is the focus of an anticipated FDA guidance document, Computer Software Assurance for Manufacturing, Operations and Quality System Software. It reflects a Case for Quality approach that places less emphasis on a compliance-first model so device manufacturers can concentrate on enhancing device quality and patient safety. Learn more on our Computer Software Assurance (CSA) page.
How is CSA different from a traditional compliance approach?
Where traditional approaches lean heavily on documentation and a compliance mindset, the FDA is leaning toward a Case for Quality (CfQ) approach. The goal is to reduce perceived regulatory burden and outdated practices that have slowed the adoption of automated systems and new technologies, while keeping device quality and patient safety as the priority.
Why is the FDA introducing this guidance?
The FDA identified two issues: the industry lags in implementing automated systems and new technologies because of a lack of clarity, outdated compliance approaches, and perceived regulatory burden; and companies often struggle to understand the root cause of issues needed to improve product quality. The new guidance is intended to address both.
Who should read this white paper?
It is written for quality, regulatory, and operations professionals in medical device, pharma, and biologics organizations who validate manufacturing, operations, and quality system software and want to understand how the FDA's CSA direction affects their approach.
How does CSA relate to data integrity and Part 11?
CSA changes how organizations focus their validation effort, but it works alongside existing expectations for 21 CFR Part 11 and data integrity in life sciences. The risk-based mindset helps teams direct assurance activities where they most protect patients and data.
Download the White Paper
Get the full white paper to understand how the FDA's anticipated Computer Software Assurance guidance can streamline your software systems and sharpen your focus on quality. Download the white paper to continue reading. Have questions about applying CSA in your organization? Contact us to talk with our team.
About the Author
Sandy Hedberg has over 20 years of professional experience in quality and regulatory affairs in medical device, pharma, and biologics industries. She has participated in assisting companies with responses to consent decrees and audit findings to the FDA. She has extensive experience in risk analysis, creation of quality procedures, computer system validation, auditing, and authoring regulatory submissions.